🇺🇸 FDA
Pipeline program

SARS-CoV-2 mRNA Vaccine ARCT-021

RG1125827

Phase 2 mab active

Quick answer

SARS-CoV-2 mRNA Vaccine ARCT-021 for Hematopoietic and Lymphatic System Neoplasm is a Phase 2 program (mab) at Arcturus Therapeutics Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcturus Therapeutics Holdings
Indication
Hematopoietic and Lymphatic System Neoplasm
Phase
Phase 2
Modality
mab
Status
active

Clinical trials